Exact Mass: 379.08043180000004
Exact Mass Matches: 379.08043180000004
Found 246 metabolites which its exact mass value is equals to given mass value 379.08043180000004,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
S-Lactoylglutathione
C13H21N3O8S (379.10493060000005)
S-Lactoylglutathione is a substrate of lactoylglutathione lyase [EC 4.4.1.5] in pyruvate metabolism (KEGG). Another enzyme, glyoxalase I, synthesizes this compound by converting methylglyoxal and reduced glutathione to S-lactoylglutathione. S-D-lactoylglutathione can be hydrolysed by thiolesterases to reduced glutathione and D-lactate but also converted to N-D-lactoylcysteinylglycine and N-D-lactoylcysteine by gamma-glutamyl transferase and dipeptidase (PMID: 8632674). S-lactoylglutathione has also been shown to modulate microtubule assembly (PMID: 690442). [HMDB]. S-Lactoylglutathione is found in many foods, some of which are blackcurrant, oat, pomegranate, and brussel sprouts. S-Lactoylglutathione is a substrate of lactoylglutathione lyase [EC 4.4.1.5] in pyruvate metabolism (KEGG). Another enzyme, glyoxalase I, synthesizes this compound by converting methylglyoxal and reduced glutathione to S-lactoylglutathione. S-D-lactoylglutathione can be hydrolysed by thiolesterases to reduced glutathione and D-lactate but also converted to N-D-lactoylcysteinylglycine and N-D-lactoylcysteine by gamma-glutamyl transferase and dipeptidase (PMID: 8632674). S-lactoylglutathione has also been shown to modulate microtubule assembly (PMID: 690442). Acquisition and generation of the data is financially supported in part by CREST/JST. D000970 - Antineoplastic Agents KEIO_ID L016; [MS3] KO009026 KEIO_ID L016; [MS2] KO009024 KEIO_ID L016
2-Bromo-5-hydroxy-N-(4-hydroxyphenethyl)-4-methoxy-N-methylbenzamide
C17H18BrNO4 (379.04191280000003)
6-Thioguanosine monophosphate
C10H14N5O7PS (379.03515440000007)
6-Thioguanosine monophosphate is a metabolite of tioguanine. Tioguanine, formerly thioguanine, is a drug that is used in the treatment of cancer. It belongs to the family of drugs called antimetabolites. It is a guanine analog. (Wikipedia) Norcodeine
Gonyautoxin V
Gonyautoxin V is found in mollusks. Gonyautoxin V is produced by Gonyaulax and Protogonyaulax species. Production by Gonyaulax and Protogonyaulax subspecies Gonyautoxin V is found in mollusks. D009676 - Noxae > D011042 - Poisons > D008978 - Mollusk Venoms D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D009676 - Noxae > D011042 - Poisons > D014688 - Venoms
Hyaluronan biosynthesis, precursor 1
This compound belongs to the family of N-acyl-alpha-hexosamines. These are carbohydrate derivatives containing a hexose moeity in which the oxygen atom is replaced by an n-acyl group.
(R)-S-lactoylglutathionate(1-)
C13H21N3O8S (379.10493060000005)
(R)-S-lactoylglutathionate(1-) is also known as (R)-S-Lactoylglutathionic acid anion. (R)-S-lactoylglutathionate(1-) is considered to be slightly soluble (in water) and acidic
Griseolic acid
Methyl 2-(2-acetoxy-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate
C18H18ClNO4S (379.0645018000001)
2H-1-Benzopyran-2-one, 7-[[2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl]oxy]-4-methyl-
2-({6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl}sulfanyl)acetamide
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists BAY 60-6583 is a potent and high-affinity agonist of adenosine A2B receptor (EC50?= 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with Ki values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model[1][5].
[2,3-e]-1,2-Thiazine-6-sulfonamide 1,1-Dioxide 1
C12H17N3O5S3 (379.03303120000004)
Cyclopenthiazide
C - Cardiovascular system > C03 - Diuretics > C03A - Low-ceiling diuretics, thiazides > C03AA - Thiazides, plain D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators
Dimethane sulfonate
N-(p-Toluenesulfonyl)-L-phenylalanyl Chloromethyl Ketone
C18H18ClNO4S (379.0645018000001)
2-Amino-5-[[1-[carboxymethyl(2-hydroxypropanoyl)amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid
C13H21N3O8S (379.10493060000005)
[(2R,5R)-5-(2-Amino-6-sulfanylidene-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
C10H14N5O7PS (379.03515440000007)
Cyclohexanecarboxamide, N-(2-((ethylsulfonyl)amino)-5-(trifluoromethyl)-3-pyridinyl)-
C15H20F3N3O3S (379.11774060000005)
12-Hydroxydihydrochelirubine
A benzophenanthridine alkaloid comprising dihydrochelirubine carrying a hydroxy substituent at the 12-position.
3-(2,3-Dihydro-1H-indol-1-yl)-2-{[5-(trifluoromethyl)-2-pyridyl]sulfonyl}acrylonitrile
Pyridinium-3,5-biscarboxylic acid mononucleotide; P2CMN; Pyridin-1-ium-3,5-dicarboxylate mononucleotide; Pyridinium-3,5-biscarboxylate mononucleotide
2-(4-Hydroxyphenyl)-2-(5-oxopyrrolidine-2-yl)-4-(3,4-dihydroxyphenyl)-4-cyclopentene-1,3-dione
6-methoxy-13-methyl-13,14-dihydro-[1,3]dioxolo[4,5-i][1,3]dioxolo[4,5:4,5]benzo[1,2-c]phenanthridin-14-ol|Chelirubin|chelirubine
2-deoxy-N-glycoloyl-9-O-lactoyl-2,3-didehydroneuraminic acid
Hymecromone, O-(2-Acetamido-2-deoxy-beta-D-glucopyranoside)
Coumarins
Cys Gly Asn Ser
C12H21N5O7S (379.11616360000005)
Cys Gly Ser Asn
C12H21N5O7S (379.11616360000005)
Cys Asn Gly Ser
C12H21N5O7S (379.11616360000005)
Cys Asn Ser Gly
C12H21N5O7S (379.11616360000005)
Cys Ser Gly Asn
C12H21N5O7S (379.11616360000005)
Cys Ser Asn Gly
C12H21N5O7S (379.11616360000005)
Gly Cys Asn Ser
C12H21N5O7S (379.11616360000005)
Gly Cys Ser Asn
C12H21N5O7S (379.11616360000005)
Gly Asn Cys Ser
C12H21N5O7S (379.11616360000005)
Gly Asn Ser Cys
C12H21N5O7S (379.11616360000005)
Gly Ser Cys Asn
C12H21N5O7S (379.11616360000005)
Gly Ser Asn Cys
C12H21N5O7S (379.11616360000005)
cyclopenthiazide
C - Cardiovascular system > C03 - Diuretics > C03A - Low-ceiling diuretics, thiazides > C03AA - Thiazides, plain D045283 - Natriuretic Agents > D004232 - Diuretics > D049993 - Sodium Chloride Symporter Inhibitors C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators
Asn Cys Gly Ser
C12H21N5O7S (379.11616360000005)
Asn Cys Ser Gly
C12H21N5O7S (379.11616360000005)
Asn Gly Cys Ser
C12H21N5O7S (379.11616360000005)
Asn Gly Ser Cys
C12H21N5O7S (379.11616360000005)
Asn Ser Cys Gly
C12H21N5O7S (379.11616360000005)
Asn Ser Gly Cys
C12H21N5O7S (379.11616360000005)
Ser Cys Gly Asn
C12H21N5O7S (379.11616360000005)
Ser Cys Asn Gly
C12H21N5O7S (379.11616360000005)
Ser Gly Cys Asn
C12H21N5O7S (379.11616360000005)
Ser Gly Asn Cys
C12H21N5O7S (379.11616360000005)
Ser Asn Cys Gly
C12H21N5O7S (379.11616360000005)
Ser Asn Gly Cys
C12H21N5O7S (379.11616360000005)
Chondroitin
4-(4-fluorobenzoyl)piperidine p-toluenesulfonate
C19H22FNO4S (379.12535040000006)
N-(p-Hydroxyphenethyl)-N-(2-bromo-5-hydroxy-4-methoxybenzyl)formamide
C17H18BrNO4 (379.04191280000003)
Urea, N-(4-chlorophenyl)-N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]- (9CI)
Urea, N-(2-chlorophenyl)-N-[2-[(3-cyano-8-methyl-2-quinolinyl)amino]ethyl]- (9CI)
Urea, N-(2-chlorophenyl)-N-[2-[(3-cyano-6-methyl-2-quinolinyl)amino]ethyl]- (9CI)
4-methylumbelliferyl-2-acetamido-2-deoxy-alpha-d-glucopyranoside
METHYL 4-(((BENZYLOXY)CARBONYL)AMINO)-2-FLUORO-[1,1-BIPHENYL]-3-CARBOXYLATE
METHYL 4-(((BENZYLOXY)CARBONYL)AMINO)-6-FLUORO-[1,1-BIPHENYL]-3-CARBOXYLATE
4-Methylumbelliferyl-N-acetyl-beta-D-galactosaminide hydrate
6-Oxo-2-phenyl-5-[[(phenylmethoxy)carbonyl]amino]-1(6H)-pyrimidineacetic acid
1,2,3-Trimethyl-1-benzyl-1H-benzo[e]indolium bromide
C22H22BrN (379.09355120000004)
(S)-Fmoc-2-amino-4,4,4-trifluoro-butyric acid
C19H16F3NO4 (379.10313720000005)
2-[(dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propyl [R-(R*,R*)]-aminoacetate
ETHYL 4-(3,5-DICHLOROPHENOXY)-1,3-DIMETHYL-1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXYLATE
2-(3-BROMO-PHENYL)-6-(4-METHOXY-PHENYL)-PYRAZOLO[1,5-A]PYRIMIDINE
C19H14BrN3O (379.03201740000003)
benzyltrimethylammonium 1,1,3,3,3-pentafluoro-2-hydroxypropanesulfonate
C13H18F5NO4S (379.0876648000001)
2-[4-(2-phenyl-1,3-thiazol-4-yl)anilino]-1,3-thiazole-4-carboxylic acid
(1-methylpiperidin-4-yl) 2-chloro-2,2-diphenylacetate,hydrochloride
4-[(2E)-2-(8-oxoquinolin-5-ylidene)hydrazinyl]naphthalene-1-sulfonic acid
C19H13N3O4S (379.0626738000001)
FMOC-D,L-ALPHA-AMINO-2-THIOPHENACETIC ACID
C21H17NO4S (379.08782420000006)
TERT-BUTYL 4-(5-BROMO-1H-INDAZOL-3-YL)PIPERIDINE-1-CARBOXYLATE
4,11-diamino-2-(3-methoxypropyl)-1H-Naphth[2,3-f]isoindole-1,3,5,10(2H)-tetrone
N-methyl-2-nitro-4-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxyaniline
sodium,2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate
C19H15ClNNaO4 (379.0587260000001)
4-(3-(2,5-DIFLUOROPHENYL)-5,5-DIMETHYL-4-OXO-4,5-DIHYDROFURAN-2-YL)BENZENESULFONAMIDE
C18H15F2NO4S (379.0689814000001)
5-[(3-chlorophenyl)azo]-1,2-dihydro-6-hydroxy-4-methyl-2-oxo-1-(phenylamino)nicotinonitrile
C19H14ClN5O2 (379.08359740000003)
(4-N-(Benzhydryloxycarbonyl)cytosine)-1-acetic acid
3-BROMO-1-(4-[5-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-1,4-DIAZEPAN-1-YL)PROPAN-1-ONE
L-689,560
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists
N-cyclopentyl-5-(4-iodophenyl)-2-methylpyrimidin-4-amine
C16H18IN3 (379.05454180000004)
DesMethyl BendaMustine Hydrochloride
C15H20Cl3N3O2 (379.06210300000004)
(3-Chloro-5-trifluoroMethyl-3,4,5,6-tetrahydro-2H-[1,2]bipyridinyl-3-yl)-carbaMic acid tert-butyl ester
4-Methylumbelliferyl 2-amino-2-deoxy-a-D-glucopyranoside
6-BROMO-1-(TETRAHYDRO-2H-PYRAN-2-YL)-N-(TETRAHYDRO-2H-PYRAN-4-YL)-1H-INDAZOL-3-AMINE
5-(3-((2S)-(1,4-Benzodioxan-2-ylmethyl)amino)propoxy)-1,3-benzodioxol hydrochloride
C19H22ClNO5 (379.11864320000007)
Fuzapladib
C15H20F3N3O3S (379.11774060000005)
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C2144 - Endothelial-Specific Integrin/Survival Signaling Inhibitor D004791 - Enzyme Inhibitors > D064801 - Phospholipase A2 Inhibitors C308 - Immunotherapeutic Agent > C574 - Immunosuppressant Fuzapladib (IS-741), an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site[1][2].
Dimethane sulfonate
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
Methyl 2-(2-acetoxy-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetate
C18H18ClNO4S (379.0645018000001)
gamma-Glutamyl-cysteinyl-glutamic acid
C13H21N3O8S (379.10493060000005)
2-chloro-N-(7-methyl-9-oxo-2-thioxanthenyl)benzamide
C21H14ClNO2S (379.04337340000006)
2-(4-chlorophenyl)-N-[4-[5-(2-furanyl)-1,3,4-oxadiazol-2-yl]phenyl]acetamide
C20H14ClN3O3 (379.0723644000001)
N-(4,7-dimethyl-1,3-benzothiazol-2-yl)-4-(2,5-dioxo-1-pyrrolidinyl)benzamide
C20H17N3O3S (379.09905720000006)
4-amino-3-(4-ethoxyphenyl)-N-(2-oxolanylmethyl)-2-sulfanylidene-5-thiazolecarboxamide
2-(4-benzofuro[3,2-d]pyrimidinylthio)-N-(2-ethoxyphenyl)acetamide
C20H17N3O3S (379.09905720000006)
2-[[1-(phenylmethyl)-3-indolyl]thio]-N-(2-thiazolyl)acetamide
3-[Isopropyl(4-methylbenzoyl)amino]-5-phenylthiophene-2-carboxylic acid
C22H21NO3S (379.1242076000001)
3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
C18H14BrN5 (379.04325040000003)
3-Bromo-6-Phenyl-N-(Pyrimidin-5-Ylmethyl)imidazo[1,2-A]pyridin-8-Amine
C18H14BrN5 (379.04325040000003)
3-Bromo-5-Phenyl-N-(Pyrimidin-5-Ylmethyl)pyrazolo[1,5-A]pyridin-7-Amine
C18H14BrN5 (379.04325040000003)
3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
C18H14BrN5 (379.04325040000003)
Pyridoxyl-glutamic acid-5-monophosphate
C13H20N2O9P+ (379.09063800000007)
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GalpNAc
An amino disaccharide consisting of N-acetyl-beta-D-galactosamine having a 4-deoxy-alpha-L-threo-hex-4-enopyranuronosyl residue attached at the 3-position.
Meticillin sodium
C17H19N2O6S- (379.09637740000005)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
(2E,6E)-3,7,11-Trimethyldodeca-2,6,10-trien-1-yl diphosphate
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
2-Amino-5-formylamino-6-(5-phospho-D-ribosylamino)pyrimidin-4(3H)-one
[(2R,3S,4S,5R,6R)-3,4,5-trihydroxy-6-(4-nitrophenoxy)oxan-2-yl]methyl phosphate
(2R,3R,4S)-2-[(2R,3R,4R,5R)-5-acetamido-4,6-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
4-Cyanobenzoic acid [6-[[(4-methyl-2-pyrimidinyl)thio]methyl]-4-oxo-3-pyranyl] ester
C19H13N3O4S (379.0626738000001)
6-(4-fluoro-1,3-benzodioxol-5-yl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine
(2-Chloro-5-nitrophenyl)(4-(3-chlorophenyl)piperazin-1-yl)methanone
2-[[2-(4-Ethoxy-3-methoxyphenyl)-4-thiazolyl]methylthio]-5-methyl-1,3,4-thiadiazole
N-[1-(2-chloro-6-fluorobenzyl)-4-piperidinyl]-N-(4-fluorophenyl)urea
5-(3,4-Dimethoxyphenyl)-2-(4-methylphenyl)-4-thieno[2,3-d][1,3]oxazinone
C21H17NO4S (379.08782420000006)
N-[1-(2-methoxyphenyl)-5-benzimidazolyl]benzenesulfonamide
C20H17N3O3S (379.09905720000006)
N-[4-(diethylamino)-2-methylphenyl]-2-[(2-nitro-3-thiophenyl)thio]acetamide
Methyl 5-chloro-4-{[3-(4-chlorophenyl)acryloyl]amino}-2-methoxybenzoate
C18H15Cl2NO4 (379.03780900000004)
[[2-[5-(2-Chlorophenyl)-1-tetrazolyl]-6,8-dioxabicyclo[3.2.1]octan-4-ylidene]amino]thiourea
N-(4-oxo-2-phenyl-1,2-dihydroquinazolin-3-yl)benzenesulfonamide
C20H17N3O3S (379.09905720000006)
2-(4-chlorophenoxy)-N-(2-pyridin-4-yl-1,3-benzoxazol-5-yl)acetamide
C20H14ClN3O3 (379.0723644000001)
2-(2-chlorophenyl)-9-(3-methylphenyl)-8-oxo-7H-purine-6-carboxamide
C19H14ClN5O2 (379.08359740000003)
4-(2,5-dimethoxyphenyl)-3-(3-phenyl-1H-pyrazol-5-yl)-1H-1,2,4-triazole-5-thione
2-(5-chloro-2-pyridinyl)-3-(4-ethoxyanilino)-3H-isoindol-1-one
isopropyl 4-{[(4-bromo-1-ethyl-1H-pyrazol-5-yl)carbonyl]amino}benzoate
C16H18BrN3O3 (379.05314580000004)
N-[[3-chloro-2-(1-piperidinyl)anilino]-sulfanylidenemethyl]-2-thiophenecarboxamide
(5E)-3-[(2-fluorophenyl)methyl]-5-[[1-(4-fluorophenyl)pyrrol-2-yl]methylidene]imidazolidine-2,4-dione
[4-[(E)-(pyridine-2-carbonylhydrazinylidene)methyl]phenyl] 2-chlorobenzoate
C20H14ClN3O3 (379.0723644000001)
2-[[5-(6-methyl-1H-benzimidazol-2-yl)-2-pyridinyl]thio]-N-(5-methyl-3-isoxazolyl)acetamide
4-(1-methylsulfonyl-2,3-dihydroindol-5-yl)-N-(2-oxolanylmethyl)-2-thiazolamine
1-[2-(4-Methylphenyl)-3-indolizinyl]-2-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]ethanone
Molybdopterin synthase intermediate
C10H14N5O7PS (379.03515440000007)
tetracenomycin D3(1-)
A hydroxy monocarboxylic acid anion that is the conjugate base of tetracenomycin F1, obtained by deprotonation of the carboxy group.
N-(2-chloroethyl)-N-(6-chloro-2-methoxyacridin-9-yl)propane-1,3-bis(aminium)
N-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]-1,3-benzodioxole-5-carboxamide
C19H13N3O6 (379.08043180000004)
methanesulfonic acid [(2R,5R)-2-(6-amino-2-chloro-9-purinyl)-4-hydroxy-5-(hydroxymethyl)-3-oxolanyl] ester
4-chloro-N-(3-hydroxy-2-methylindol-1-yl)-3-sulfamoylbenzamide
C16H14ClN3O4S (379.03935140000004)
2-[[3,4-Dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]amino]acetic acid
[(3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-phosphonooxyoxan-2-yl] 2-aminobenzoate
4-chloro-N-(5-hydroxy-2-methylindol-1-yl)-3-sulfamoylbenzamide
C16H14ClN3O4S (379.03935140000004)
4-chloro-N-[(2S)-2-methyl-3-oxo-2H-indol-1-yl]-3-sulfamoylbenzamide
C16H14ClN3O4S (379.03935140000004)
2-(alpha-Furyl)-6-hydroxychromanone para-nitrobenzoate
C20H13NO7 (379.06919880000004)
(R)-S-Lactoylglutathione
C13H21N3O8S (379.10493060000005)
The S-[(R)-lactoyl] derivative of glutathione. It is an intermediate in the pyruvate metabolism. D000970 - Antineoplastic Agents
Gonyautoxin V
D009676 - Noxae > D011042 - Poisons > D008978 - Mollusk Venoms D009676 - Noxae > D011042 - Poisons > D008387 - Marine Toxins D009676 - Noxae > D011042 - Poisons > D014688 - Venoms
3-(4-Deoxy-alpha-L-threo-hex-4-enopyranosyluronic acid)-2-acetamido-2-deoxy-D-glucose
N-acetyl-3-O-(4-deoxy-alpha-L-threo-hex-4-enopyranosyluronic acid)-D-galactosamine
2-({6-Amino-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl}sulfanyl)acetamide
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058913 - Purinergic Agonists BAY 60-6583 is a potent and high-affinity agonist of adenosine A2B receptor (EC50?= 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with Ki values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model[1][5].
beta-D-4-deoxy-Delta(4)-GlcpA-(1->3)-beta-D-GlcpNAc
An amino disaccharide consisting of N-acetyl-beta-D-glucosamine having a 4-deoxy-alpha-L-threo-hex-4-enopyranuronosyl residue attached at the 3-position.
5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)-1,3-benzothiazol-6-yl hydrogen sulfate
An aryl sulfate obtained by sulfation of the phenolic hydroxy group of the anti-inflammatory drug, E3040. It is one of the major metabolites of E3040.
3-(4-deoxy-beta-D-gluc-4-enosyluronic acid)-N-acetyl-D-glucosamine
An amino disaccharide consisting of N-acetyl-beta-D-glucosamine having a 4-deoxy-alpha-L-threo-hex-4-enopyranuronosyl residue attached at the 3-position.
2-trans,6-trans-farnesyl diphosphate(3-)
An organophosphate oxoanion that is the trianion obtained by removal of the three protons from the diphosphate group of 2-trans,6-trans-farnesyl diphosphate.
Vicagrel
C18H18ClNO4S (379.0645018000001)
Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease[1][2].
(3s)-3-[(1r)-1-[(2s,5s)-3,6-dihydroxy-5-[(s)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
C17H21N3O5S (379.12018560000007)
3-(1-hydroxyethyl)-6-(1h-indol-3-ylmethyl)-3,6-bis(methylsulfanyl)pyrazine-2,5-diol
n-sulfo{[(3as,4r,10as)-10,10-dihydroxy-2,6-diimino-hexahydro-1h-pyrrolo[1,2-c]purin-4-yl]methoxy}carboximidic acid
4-(3,4-dihydroxyphenyl)-2-(5-hydroxy-3,4-dihydro-2h-pyrrol-2-yl)-2-(4-hydroxyphenyl)cyclopent-4-ene-1,3-dione
(2s)-2-amino-4-{[(1r)-1-(carboxymethyl-c-hydroxycarbonimidoyl)-2-{[(2r)-2-hydroxypropanoyl]sulfanyl}ethyl]-c-hydroxycarbonimidoyl}butanoic acid
C13H21N3O8S (379.10493060000005)
5- O- nitrosouridine
C12H15ClFN5O6 (379.06948520000003)
{"Ingredient_id": "HBIN011870","Ingredient_name": "5- O- nitrosouridine","Alias": "5-O-nitrosouridine","Ingredient_formula": "C12H15ClFN5O6","Ingredient_Smile": "C1C(C(OC1N2C=C(C(=O)NC2=O)F)CO)NC(=O)N(CCCl)N=O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "39659;39162","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5-hydroxy-6-(hydroxymethyl)-3-(1h-indol-3-ylmethyl)-1-methyl-3,6-bis(methylsulfanyl)pyrazin-2-one
[(3as,4r,9s,10s,10as)-10-hydroxy-2,6-diimino-9-(sulfooxy)-octahydropyrrolo[1,2-c]purin-4-yl]methoxycarboximidic acid
[(3ar,4r,9s,10s,10as)-4-[(carbamoyloxy)methyl]-10-hydroxy-2,6-diimino-octahydropyrrolo[1,2-c]purin-9-yl]oxidanesulfonic acid
3-{1-[3,6-dihydroxy-5-(methanesulfinylmethyl)-2,5-dihydropyrazin-2-yl]ethyl}-3-hydroxy-1-methylindol-2-one
C17H21N3O5S (379.12018560000007)
3-hydroxy-4,5-dimethoxy-6-[2-(5-oxohexyl)-1,3-thiazol-4-yl]pyridine-2-carboximidic acid
C17H21N3O5S (379.12018560000007)
5-bromo-1-[(1s)-1-(dimethylamino)-2-(methylsulfanyl)ethyl]-9h-pyrido[3,4-b]indol-6-ol
(3s,6r)-5-hydroxy-3-(hydroxymethyl)-6-(1h-indol-3-ylmethyl)-1-methyl-3,6-bis(methylsulfanyl)pyrazin-2-one
(3s)-3-[(1r)-1-[(2s,5s)-3,6-dihydroxy-5-[(r)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
C17H21N3O5S (379.12018560000007)
(5r)-12'-methyl-3,4',6',10,12-pentaoxa-12'-azaspiro[tricyclo[7.3.0.0²,⁶]dodecane-5,11'-tricyclo[7.5.0.0³,⁷]tetradecane]-1(9),1',2(6),3'(7'),7,8',13'-heptaene-4,10'-dione
C20H13NO7 (379.06919880000004)
(3r)-3-[(1r)-1-[(2s,5r)-3,6-dihydroxy-5-[(r)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
C17H21N3O5S (379.12018560000007)
(2r)-4-(3,4-dihydroxyphenyl)-2-[(2r)-5-hydroxy-3,4-dihydro-2h-pyrrol-2-yl]-2-(4-hydroxyphenyl)cyclopent-4-ene-1,3-dione
(3s,6s)-5-hydroxy-6-(hydroxymethyl)-3-(1h-indol-3-ylmethyl)-1-methyl-3,6-bis(methylsulfanyl)pyrazin-2-one
(23s)-12-methoxy-24-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.0²,¹⁰.0⁴,⁸.0¹⁴,²².0¹⁷,²¹]tetracosa-1(13),2,4(8),9,11,14,16,21-octaen-23-ol
(2s,5r,6r,6as)-5-(6-aminopurin-9-yl)-2-[carboxy(hydroxy)methyl]-6-hydroxy-5h,6h,6ah-furo[3,2-b]furan-2-carboxylic acid
(4s,5r,6r)-6-{[(3r,4r,5r,6r)-2,5-dihydroxy-3-[(1-hydroxyethylidene)amino]-6-(hydroxymethyl)oxan-4-yl]oxy}-4,5-dihydroxy-5,6-dihydro-4h-pyran-2-carboxylic acid
12-methoxy-24-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.0²,¹⁰.0⁴,⁸.0¹⁴,²².0¹⁷,²¹]tetracosa-1(13),2,4(8),9,11,14,16,21-octaen-23-ol
(3r)-3-[(1r)-1-[(2s,5r)-3,6-dihydroxy-5-[(s)-methanesulfinylmethyl]-2,5-dihydropyrazin-2-yl]ethyl]-3-hydroxy-1-methylindol-2-one
C17H21N3O5S (379.12018560000007)
(2r,5r,6r,6ar)-5-(6-aminopurin-9-yl)-2-[(s)-carboxy(hydroxy)methyl]-6-hydroxy-5h,6h,6ah-furo[3,2-b]furan-2-carboxylic acid
3-hydroxy-4,5-dimethoxy-6-[2-(4-oxohexyl)-1,3-thiazol-4-yl]pyridine-2-carboximidic acid
C17H21N3O5S (379.12018560000007)
(3s,6r)-5-hydroxy-6-(hydroxymethyl)-3-(1h-indol-3-ylmethyl)-1-methyl-3,6-bis(methylsulfanyl)pyrazin-2-one
3-hydroxy-4,5-dimethoxy-6-[2-(3-methyl-4-oxopentyl)-1,3-thiazol-4-yl]pyridine-2-carboximidic acid
C17H21N3O5S (379.12018560000007)